When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CHGCF - Chugai's satralizumab shows positive effect in late-stage study in inflammatory CNS disorder
Chugai Pharmaceutical
A Phase 3 clinical trial, SAkuraSky Study, evaluating Chugai Pharmaceutical's (OTCPK:CHGCF) satralizumab as add-on therapy in patients with neuromyelitis optica spectrum disorder (NMOSD) met the primary endpoint. The results were presented at ECTRIMS in Berlin.
More news on: Chugai Pharmaceutical Co., Ltd., Healthcare stocks news,